Prevalence and correlates of metabolic syndrome in patients with rheumatoid arthritis in Argentina

Journal of Clinical Rheumatology

Volumn 19, Issue 8, 2013, Pages 439-443

  Salinas, María Jezabel Haye ^a   Bertoli, Ana María ^b   Lema, Luís ^c   Saucedo, Carla ^d   Rosa, Javier ^d   Quintana, Rosana ^e   Bellomio, Verónica ^f   Agüero, Santiago ^g   Spindler, Walter ^h   Tamborenea, Natalia ⁱ   Schimid, Marcela ^j   Ceccato, Federico ^j   Sala, Jose Pablo ^c   Paira, Sergio ^j   Spindler, Alberto ^h   Soriano, Enrique R ^d   Estel, Bernardo A Pons ^e   Caeiro, Francisco ^a   Alvarellos, Alejandro ^a   Saurit, Verónica ^a  

^a HOSPITAL PRIVADO   (Argentina)

^b Instituto Reumatológico Strusberg   (Argentina)

^c Inst de Cardiol Hospital Italiano   (Argentina)

^d HOSPITAL ITALIANO DE BUENOS AIRES   (Argentina)

^e Hospital Provincial de Rosario   (Argentina)

^f Hospital A C Padilla   (Argentina)

^g Centro de Rehabilitación II   (Argentina)

^h Centro Medico Privado de Reumatologia   (Argentina)

ⁱ Reumatólogo en Organización Médica de Investigación   (Argentina)

^j Hospital Jose M Cullen   (Argentina)

more..

Author keywords

Adipose tissue; Cardiovascular; DMARDs; Epidemiology; Rheumatoid arthritis

Indexed keywords

CYCLIC CITRULLINATED PEPTIDE ANTIBODY; RHEUMATOID FACTOR;

ADULT; ARGENTINA; ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE ACTIVITY; DISEASE ACTIVITY SCORE; DISEASE DURATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PREVALENCE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS;

ADULT; AGED; ARGENTINA; ARTHRITIS, RHEUMATOID; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREVALENCE;

EID: 84889258607     PISSN: 10761608     EISSN: 15367355     Source Type: Journal    
DOI: 10.1097/RHU.0000000000000039     Document Type: Article

References (37)

1. Michaud K, Wolfe F. Comorbidities in rheumatoid arthritis. Best Pract Res Clin Rheumatol. 2007;21:885-906. (Pubitemid 47377810)
2. Wasko MC. Comorbid conditions in patients with rheumatic diseases: an update. Curr Opin Rheumatol. 2004;16:109-113. (Pubitemid 38280944)
3. Mikuls TR. Co-morbidity in rheumatoid arthritis. Best Pract Res Clin Rheumatol. 2003;17:729-752.
4. Ferraccioli G, Gremese E. Adiposity, joint and systemic inflammation: the additional risk of having a metabolic syndrome in rheumatoid arthritis. Swiss Med Wkly. 2011:141-151.
5. Crowson SC, Gabriel SE. Towards improving cardiovascular risk management in patients with rheumatoid arthritis: the need for accurate risk assessment. Ann Rheum Dis. 2011;70:719-721.
6. Aviña-Zubieta JA, Choi HK, Sadatsafavi M, et al. Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum. 2008;59:1690-1697.
7. Dhawan SS, Quyyumi AA. Rheumatoid arthritis and cardiovascular disease. Curr Atheroscler Rep. 2008;10:128-133. (Pubitemid 351486147)
8. Nurmohamed MT, Kitas G. Cardiovascular risk in rheumatoid arthritis and diabetes: how does it compare and when does it start? Ann Rheum Dis. 2011;70:881-883.
9. van Doornum S, McColl G, Wicks IP. Accelerated atherosclerosis an extraarticular feature of rheumatoid arthritis? Arthritis Rheum. 2002;46:862-873. (Pubitemid 34303796)
10. Sidiropoulos PI, Karvounaris SA, Boumpas DT. Metabolic syndrome in rheumatic diseases: epidemiology, pathophysiology, and clinical implications. Arthritis Res Ther. 2008;10:207.
11. Brady SR, de Courten B, Reid CM, et al. The role of traditional cardiovascular risk factors among patients with rheumatoid arthritis. J Rheumatol. 2009;36:34-40.
12. Peter MJL, Symmons DPM, McCarey D, et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis. 2010;69:325-331.
13. Karvounaris SA, Sidiropoulos JA, Spanakis EK, et al. Metabolic syndrome is common among middle-to-older aged Mediterranean patients with rheumatoid arthritis and correlates with disease activity: a retrospective, crosssectional, controlled, study. Ann Rheum Dis. 2007;66:28-33. (Pubitemid 46044857)
14. Gonzalez A, Maradit Kremers H, Crowson CS, et al. Do cardiovascular risk factors confer the same risk for cardiovascular outcomes in rheumatoid arthritis patients as in non-rheumatoid arthritis patients? Ann Rheum Dis. 2008;67:64-69.
15. Chung CP, Oeser A, Solus JF, et al. Prevalence of the metabolic syndrome is increased in rheumatoid arthritis and is associated with coronary atherosclerosis. Atherosclerosis. 2008;196:756-763. (Pubitemid 351165786)
16. Snow MH, Mikuls TR. Rheumatoid arthritis and cardiovascular disease: the role of systemic inflammation and evolving strategies of prevention. Curr Opin Rheumatol. 2005;17:234-241. (Pubitemid 40616568)
17. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes. 1988;37:1595-1607. (Pubitemid 19004941)
18. Mottillo S, Filion KB, Genest J. The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. J Am Coll Cardiol. 2010;56:1113-1114.
19. Gami AS, Witt BJ, Howard DE, et al. Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies. J Am Coll Cardiol. 2007;49:403-414. (Pubitemid 46135879)
20. Galassi A, Reynolds K. Metabolic syndrome and risk of cardiovascular disease: a meta-analysis. Am J Med. 2006;119:812-819. (Pubitemid 44415613)
21. Ford ES. Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome. Diabetes Care. 2005;28:1769-1778. (Pubitemid 40923091)
22. NCEP Expert Panel: executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497.
23. Alberti KGMM, Zimmet P, Shaw J, et al. The metabolic syndromeVa new worldwide definition. The Lancet. 2005;366:1059-1062. (Pubitemid 41338752)
24. Sarmiento Méndez LM, Roca Cusachs A, Arroyo Díaz JA, et al. Comparación de las definiciones de síndromemetabólico según ATP III e IDF. Rev Clin Esp. 2008;208:333-338. (Pubitemid 351987872)
25. Monami M, Marchionni N, Masotti G, et al. IDF and ATP III definitions of metabolic syndrome in the prediction of all cause mortality in type 2 diabetic patients. Diabetes Obes Metab. 2007;9:350-353. (Pubitemid 46502054)
26. Ucar E, Huzmeli C, Guven O, et al. Frequency of metabolic syndrome among hemodialysis patients according to NCEP-ATP III and IDF definitions. Ren Fail. 2009;31:221-228.
27. Tong PC, Kong AP, So WY, et al. The usefulness of the International Diabetes Federation and the National Cholesterol Education Program's Adult Treatment Panel III definitions of the metabolic syndrome in predicting coronary heart disease in subjects with type 2 diabetes. Diabetes Care. 2007;30:1206-1211. (Pubitemid 46684649)
28. Dao HH, Do QT, Sakamoto J. Increased frequency of metabolic syndrome among Vietnamese women with early rheumatoid arthritis: a cross-sectional study. Arthritis Res Ther. 2010;12:R218.
29. Sahebari M, Goshayeshi L, Mirfeizi Z, et al. Investigation of the association between metabolic syndrome and disease activity in rheumatoid arthritis. Sci World J. 2011;11:1195-1205.
30. Sihvonen S, Korpela M, Mustila A, et al. The predictive value of rheumatoid factor isotypes, anti-cyclic citrullinated peptide antibodies, and antineutrophil cytoplasmic antibodies for mortality in patients with rheumatoid arthritis. J Rheumatol. 2005;32:2089-2094. (Pubitemid 41587850)
31. Snir O, Widhe M, von Spee C, et al. Multiple antibody reactivities to citrullinated antigens in sera from patients with rheumatoid arthritis: association with HLA-DRB1 alleles. Ann Rheum Dis. 2009; 68:736-743.
32. Farragher TM, Goodson NJ, Naseem H, et al. Association of the HLA-DRB1 gene with premature death, particularly from cardiovascular disease, in patients with rheumatoid arthritis and inflammatory polyarthritis. Arthritis Rheum. 2008;58:359-369. (Pubitemid 351294870)
33. Raterman HG, van Eijk C, Voskuyl AE, et al. The metabolic syndrome is amplified in hypothyroid rheumatoid arthritis patients: a cross-sectional study. Ann Rheum Dis. 2010;69:39-42.
34. Toms TE, Panoulas VP, John H, et al. Methotrexate therapy associates with reduced prevalence of the metabolic syndrome in rheumatoid arthritis patients over the age of 60Vmore than just an anti-inflammatory effect? A cross sectional study. Arthritis Res Ther. 2009;11:R110.
35. Rho YH, Oeser A, Chung CP, et al. Drugs used in the treatment of rheumatoid arthritis: relationship between current use and cardiovascular risk factors. Arch Drug Inf. 2009;2:34-40.
36. Wasko MCM, Hurbert HB, Lingala VB, et al. Hydroxychloroquine and risk of diabetes in patients with rheumatoid arthritis. JAMA. 2007;298:187-193. (Pubitemid 47057765)
37. Gonzalez A, Kremers HM, Crowson CS, et al. The widening mortality gap between rheumatoid arthritis patients and the general population. Arthritis Rheum. 2007;56:3583-3587. (Pubitemid 350100691)